Skip to main content
Elsevier

Epigenetic Therapy by Phytochemicals in Lung Cancer

Mechanisms, Therapeutic Potential, and Clinical Implications

  • 1st Edition - May 29, 2026
  • Latest edition
  • Editors: Umesh Kumar, Deepak Parashar, Sandeep Kumar Singh, Sachin Kumar
  • Language: English

Epigenetic Therapy by Phytochemicals in Lung Cancer provides a comprehensive exploration of the intersection between cancer epigenetics and phytotherapy, focusing on lung cancer… Read more

Back to School

Start strong. Study with purpose.

Save up to 25% on trusted learning resources

Shop now

Description

Epigenetic Therapy by Phytochemicals in Lung Cancer provides a comprehensive exploration of the intersection between cancer epigenetics and phytotherapy, focusing on lung cancer. The book emphasizes the role of epigenetic alterations in cancer progression and presents phytochemicals as promising agents capable of reversing these changes, thereby offering innovative therapeutic strategies. The content examines the mechanisms by which epigenetic modifications, such as DNA methylation and histone modification, contribute to lung cancer. It details specific phytochemicals—like curcumin, resveratrol, and quercetin—and their potential to modulate these pathways, while discussing clinical applications, challenges, and future research directions. For academics, this book equips researchers and healthcare professionals with evidence-based insights into alternative cancer therapies, enhancing understanding of multi-targeted approaches. It serves as a valuable reference for teaching and further research, promoting a more inclusive perspective in cancer care and addressing disparities in treatment access and efficacy.

Key features

  • Collates current research on epigenetic changes in lung cancer and how specific phytochemicals interact with these mechanisms to halt or reverse tumor progression
  • Discusses the therapeutic potential of phytochemicals as low-toxicity alternatives or adjuncts to conventional lung cancer treatments
  • Identifies gaps in current research and outlines promising areas for study, helping researchers and practitioners pinpoint future opportunities in developing effective phytochemical-based therapies

Readership

researchers, academics and postgraduate students in the fields of oncology, pharmacology, molecular biology, and phytotherapy

Table of contents

Part I: Introduction to lung cancer and epigenetics

1 Lung cancer
​Niktia Bhandari, Sudhanshu Shukla

2 The role of epigenetic alterations in lung cancer progression
​Shikha Kaushik, Shruti Khanna, Pooja Ghorawat, Pavan Baboo, Sneha Sharma, Rekha Panwar, Jaya Tak, Tapasya Srivastava

3 Epigenetic therapy by phytochemicals in lung cancer: Mechanism, therapeutic potential, and clinical implications
​Ravi Bhushan, Prachi Gupta, Arunima Dhurve, Kalyani Bhardwaj, Umesh Kumar, Shishir K. Gupta, Prabhaker Yadav
Part II: Phytochemicals as epigenetic modulators

4 Introduction to phytochemicals with epigenetic activity
​Pallavi Baliga, Sana Sheikh, Umesh Kumar

5 DNA methylation modulation by phytochemicals
​Rashmi Gupta, Dhiraj Kumar Singh, Umesh Kumar

6 Nature’s epigenetic tools: Histone modification control by phytochemicals in lung cancer
​Joyeeta Talukdar, Sorra Sandhya, Debabrat Baishya, Umesh Kumar

7 Impact of phytochemicals on noncoding RNAs in lung cancer
​Bibhudendu Behera, Bhupender Sahu, Garima Rathi, Umesh Kumar
Part III: Phytochemicals in lung cancer therapy—Mechanisms and evidence

8 Polyphenols as epigenetic modulators: Curcumin, resveratrol, and quercetin
​Mohini Kalra, Umesh Kumar

9 Flavonoids and epigenetic therapy in lung cancer
​Clinton Ayodeji Akanbi, Julius Oluwafemi Opatoyinbo, Solomon Olayinka Awosanya, Adebola Busola Ojo, Olorunfemi Raphael Molehin, Oluwafemi Adeleke Ojo

10 Terpenoids and their role in lung cancer epigenetic modulation
​Neha Sajwani, Shobha Dagamajalu, Umesh Kumar

11 Alkaloids and lung cancer epigenetics: Mechanistic insights and case studies
​Lakshita Tyagi, Shreeja Mishra, Simran, Garima Rathi, Umesh Kumar
Part IV: Clinical implications and future directions

12 Preclinical and clinical trials of phytochemicals in lung cancer epigenetics
​Bibhudendu Behera, Lakshita Tyagi, Shreeja Mishra, Simran, Umesh Kumar

13 Insights into clinical trials and real-world applications of phytochemicals
​Maneesh Kumar, Suman Kumar, Bibekananda Bhoi, Balarko Chakraborty, Ravikant Singh, Umesh Kumar, Sandeep Kumar

14 Challenges in phytochemical-based epigenetic therapy
​Gaurav Borse, Amol Muthal, Mahesh Ghaisas, Ravindra Kulkarni, Vaibhav Shinde, Umesh Kumar

15 Formulation and delivery systems for phytochemical-based epigenetic drugs
​Vivek Pamula, Rahaman Shaik, Shaheen Mahira

16 Combination therapies: Phytochemicals with conventional lung cancer therapies
​Umesh Kumar, Lakshita Tyagi, Simran, Shreeja Mishra, Sandeep Kumar

17 Conclusion and future perspectives in epigenetic phytotherapy for lung cancer
​Shiv Charan, Gladson David Masih, Rahul Soloman Singh, Ashutosh Singh, Benjamin Soroy, Umesh Kumar, Deeksha Pal, Bikash Medhi

18 Cancer immunotherapy, including CAR-T cell therapy and immune checkpoint inhibitors
​Manoj Kumar Jana, Vishnu Swarup, Disha Roy, Suryaprakash Tripathy, Deepesh Joshi, Neeraj Mohan Gupta, Sayantam Jana, Umesh Kumar, Sudip Das

Product details

  • Edition: 1
  • Latest edition
  • Published: June 4, 2026
  • Language: English

About the editors

UK

Umesh Kumar

Dr. Umesh Kumar is a Professor in the Department of Biosciences at IMS Ghaziabad (University Courses Campus) and has led the Research Department since 2019. Previously, he served as a Scientific Officer in the Department of Biochemistry at the University of Delhi. He earned his Ph.D. in Biomedical Sciences, focusing on "Epigenetic Regulation in Breast Carcinogenesis," from the Dr. B. R. Ambedkar Centre for Biomedical Research, University of Delhi, in 2013. Dr. Kumar's research interests include molecular diagnosis of cervical cancer, molecular epigenetics of breast carcinogenesis, CAR T-cell therapy, and tumor virology. He has published 50 research articles and contributed over 21 book chapters to reputable publishers. He has received multiple grants and has been honored with two Young Scientist Awards and one Senior Scientist Award. Additionally, he reviews for several international journals and serves as a Doctoral Research Committee (DRC) Expert member at various Indian universities.
Affiliations and expertise
Associate Director Chandigarh University Mohali, Punjab

DP

Deepak Parashar

Dr. Deepak Parashar earned his PhD in 2016 from the National Institute of Immunology and Jaipur National University, focusing on the role of SOX4 in cervical cancer. He then joined Dr. Chaluvally’s lab as a postdoctoral fellow at the Medical College of Wisconsin, where he investigated microRNAs like miR551b in breast and ovarian cancers and screened anti-cancer drugs for ovarian treatment. In 2022, he became an Assistant Professor in Dr. Janz’s lab, researching immuno-oncology in multiple myeloma (MM). His current work explores microRNAs and transcription factors like FOXM1 in the tumor immune microenvironment to enhance immunotherapies. Additionally, he studies drug resistance mechanisms and develops nanotechnology-based targeted drug delivery systems for preclinical models. Dr. Parashar has published over 50 manuscripts in prestigious journals and has over 10 years of cancer research experience, mentoring postdocs and graduate students while serving as a peer reviewer and associate editor for various journals.
Affiliations and expertise
Medical College of Wisconsin, USA

SS

Sandeep Kumar Singh

Dr. Sandeep Kumar Singh is Assistant Professor in the All India Institute of Medical Sciences (AIIMS), Nagpur, India. He obtained his PhD in Biotechnology from Banaras Hindu University and conducted postdoctoral research in the Department of Neurobiology at the University of Chicago. Dr. Singh brings 17 years of experience in neuroscience, molecular biology, neurodegenerative diseases, aging, nutraceuticals, and nanomedicines. He is a member of several scientific societies, including the American Academy of Neurology, International Society of Neurochemistry, Society of Neurochemistry, Indian Academy of Neurosciences, and Alzheimer’s and related Disorders Society of India. Dr. Singh has published five books, including Elsevier’s A New Era in Alzheimer’s Research and Genome Editing for Neurodegenerative Diseases.

Affiliations and expertise
Department of Medical Biotechnology, All India Institute of Medical Sciences, Nagpur, MH, India

SK

Sachin Kumar

Dr. Sachin Kumar is an Associate Professor in the Department of Biochemical Engineering, Harcourt Butler Technical University, Kanpur, India. He earned his PhD from AIIMS in 2010, with research focused on circulating DNA and protein markers in lung cancer, and later pursued post-doctoral training in cancer gene therapy at Virginia Commonwealth University, USA.

His current research focuses on liquid biopsy and the role of non-coding RNAs as biomarkers in lung cancer, supported by national and institutional grants. He has authored more than 50 publications in leading international journals and has been recognized with several honors, including the AIIMS Excellence Research Awards (2020, 2022) and the Young Investigator Award from the Indian Society for Study of Lung Cancer (2019).

Dr. Kumar serves on the Editorial Board of Discover Oncology and reviews for numerous high-impact journals. He is also an active member of the American Association for Cancer Research and a Life Member of the Indian Society for Study of Lung Cancer and the Indian Association for Cancer Research.

Affiliations and expertise
Associate Professor, Department of Biochemical Engineering, Harcourt Butler Technical University, Kanpur, India

View book on ScienceDirect

Read Epigenetic Therapy by Phytochemicals in Lung Cancer on ScienceDirect